Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan K Zahn

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Angewandte Chemie (International Ed. in English)|June 1, 2001
Domino Hydroformylation/Knoevenagel/Hydrogenation Reactions This work was supported by the Fonds der Chemischen Industrie (Fellowship to S.K.Z.) and the Deutsche Forschungsgemeinschaft, as well as an Alfried Krupp Award for Young University Teachers from the Krupp foundation. We thank the companies BASF and Degussa for their gift of chemicalsBernhard Breit, Stephan K. Zahn
Angewandte Chemie (International Ed. in English)|May 2, 2018
Domino Hydroformylation-Wittig ReactionsBernhard Breit, Stephan K Zahn
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 18, 2003
Diastereoselective hydroformylation of 2-substituted allylic o-DPPB-esters-on the origin of 1,2-asymmetric inductionBernhard Breit, Golo Heckmann, Stephan K Zahn
Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2017
An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitorMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Molecular Cancer Therapeutics|October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose HomeostasisMichael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
Molecular Cancer Therapeutics|July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF TherapyMichael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Angewandte Chemie (International Ed. in English)|June 1, 2001
Domino Hydroformylation/Knoevenagel/Hydrogenation Reactions This work was supported by the Fonds der Chemischen Industrie (Fellowship to S.K.Z.) and the Deutsche Forschungsgemeinschaft, as well as an Alfried Krupp Award for Young University Teachers from the Krupp foundation. We thank the companies BASF and Degussa for their gift of chemicalsBernhard Breit, Stephan K. Zahn
Angewandte Chemie (International Ed. in English)|May 2, 2018
Domino Hydroformylation-Wittig ReactionsBernhard Breit, Stephan K Zahn
Chemistry (Weinheim an Der Bergstrasse, Germany)|January 18, 2003
Diastereoselective hydroformylation of 2-substituted allylic o-DPPB-esters-on the origin of 1,2-asymmetric inductionBernhard Breit, Golo Heckmann, Stephan K Zahn
Cancer Chemotherapy and Pharmacology|May 11, 2016
A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniquesMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Cancer Chemotherapy and Pharmacology|March 1, 2017
An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitorMelanie I Titze, Otmar Schaaf, Marco H Hofmann, et al.
Molecular Cancer Therapeutics|October 7, 2015
BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose HomeostasisMichael P Sanderson, Joshua Apgar, Pilar Garin-Chesa, et al.
Molecular Cancer Therapeutics|July 22, 2017
The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF TherapyMichael P Sanderson, Marco H Hofmann, Pilar Garin-Chesa, et al.
Molecular Cancer Therapeutics|August 7, 2016
Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora KinasesPatrizia Sini, Ulrich Gürtler, Stephan K Zahn, et al.
Chemmedchem|December 4, 2020
Getting a Grip on the Undrugged: Targeting β-Catenin with Fragment-Based MethodsDirk Kessler, Moriz Mayer, Stephan K Zahn, et al.
Journal of Medicinal Chemistry|August 1, 2019
Intracellular Trapping of the Selective Phosphoglycerate Dehydrogenase (PHGDH) Inhibitor <b>BI-4924</b> Disrupts Serine BiosynthesisHarald Weinstabl, Matthias Treu, Joerg Rinnenthal, et al.
Pageof 1